Energy-assisted CRISPR cleavage and probiotic vesicle signaling platform: Microbiome reprogramming for homeostasis
Zilin Zhou1, Yingming Yang1, Fangjie Zhou1
1State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Abstract:
Pathogenic infections drive microbial dysbiosis and persistent inflammation, posing therapeutic challenges due to difficulties in precise pathogen eradication and microbiome restoration. Although CRISPR-based therapeutics enable pathogen-specific antibacterial targeting, their effectiveness in treating pathogenic infections is constrained by difficulties in navigating complex microbial ecosystems, penetrating pathogenic barriers, sustaining energy-intensive intracellular cleavage, and, critically, restoring microbial balance after pathogen clearance. Here, we engineer a probiotic vesicle-synergized CRISPR platform by encapsulating gtfB-targeting CRISPR plasmids within hybrid extracellular vesicles from probiotics and pathogenic Streptococcus mutans. The pathogen-derived vesicle component enables targeted uptake by S. mutans, facilitating intracellular cleavage of the virulence gene gtfB. Vesicle-carried endogenous adenosine triphosphate (ATP) boosts CRISPR activity, amplifying targeted DNA cleavage for potent and selective pathogen elimination. Probiotic-derived vesicle components further remodel quorum-sensing networks and immunity, restoring microbial homeostasis. This probiotic vesicle-based strategy integrates ATP-enhanced CRISPR cleavage with microbiome and immune modulation, offering a next-generation therapeutic paradigm for microbiome-associated diseases.
Insights
This study introduces a novel CRISPR-based therapy using probiotic vesicles to target pathogenic bacteria like Streptococcus mutans. The engineered vesicles enhance CRISPR
Area of Science:
- Microbiology
- Biotechnology
- Genetic Engineering
Background:
- Pathogenic infections cause microbial dysbiosis and inflammation, presenting treatment challenges.
- Current CRISPR therapeutics struggle with precise pathogen eradication and microbiome restoration in complex ecosystems.
Purpose of the Study:
- To engineer a probiotic vesicle-synergized CRISPR platform for effective treatment of pathogenic infections.
- To overcome limitations of CRISPR-based therapies in pathogen targeting and microbiome restoration.
Main Methods:
- Encapsulating CRISPR plasmids targeting the gtfB gene into hybrid extracellular vesicles from probiotics and Streptococcus mutans.
- Utilizing pathogen-derived vesicle components for targeted uptake and probiotic-derived components for immune modulation.
- Incorporating vesicle-carried adenosine triphosphate (ATP) to enhance CRISPR activity.
Main Results:
- The engineered vesicles achieved targeted intracellular cleavage of the gtfB virulence gene in S. mutans.
- Vesicle-carried ATP significantly boosted CRISPR-mediated DNA cleavage, leading to potent and selective pathogen elimination.
- Probiotic vesicle components modulated quorum-sensing networks and immunity, restoring microbial homeostasis.
Conclusions:
- The probiotic vesicle-based strategy offers a next-generation therapeutic paradigm for microbiome-associated diseases.
- This approach integrates enhanced CRISPR cleavage with microbiome and immune modulation for comprehensive treatment.
Related Concept Videos
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
CRISPR/Cas9 Genome Editing
Homologous Recombination
CRISPR
CRISPR
Microbiota Modulation by Antibiotics


